Teva Pharmaceutical Industries Limited ( NYSE: TEVA) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:00 AM ET Good morning, everyone. My name is Balaji Prasad. I'm the Senior ...

Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, ...

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy extended-release injectable suspension as a maintenance treatment for bipolar ...

Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...

In the specialty pharmaceutical segment, Teva's innovative products like Austedo and UZEDY are helping the company carve out a significant niche. The potential success of pipeline candidates such as ...

Investing.com -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (NYSE:TEVA) Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext (EPA:ENX): MEDCL), announced on February ...

The potential success of pipeline candidates such as Duvakitug and Olanzapine LAI could further enhance Teva's competitive edge in this high-value market. Analysts believe that Teva is in the ...